Biopharma’s small-to-mid-cap players are stepping up as serious acquirers. David Wild and Scrip’s Jessica Merrill unpack how companies like argenx, Insmed, Jazz, Genmab, UCB, and BioMarin are using M&amp;A to extend growth beyond their first commercial successes and what that shift means for investors, dealmaking, and the next generation of big biotechs.

Strategic Intent: The Rise Of Mid-Cap Dealmakers

Citeline Podcasts

[SPEAKER_A] Hello and welcome to a new episode of Strategic Intent, brought to you by the Invivo and Scrip teams. I'm David Wild, and today we're looking at a cohort of companies that has spent the last few years proving it can launch and commercialize drugs on its own, the small and mid-cap biopharma's. And we're looking at what those companies do next, now that they have revenue, in some cases profits. Increasingly, the answer involves buying something. My guest today is Jessica Merrill, who covers biopharma strategy and dealmaking for Scrip. Jess has been tracking this group closely, and she recently reported on this striking rise in small and mid-cap companies doing large acquisitions on their own. Jess, welcome to the podcast.

[SPEAKER_B] Hey David, thanks for having me. It's great to be here and talking about something that I've been covering quite a lot recently.

[SPEAKER_A] Yeah, great to have you. So for these small and mid-cap companies, the growth question usually comes down to a choice between investing in internal R&D and doing business development. And your recent reporting is focused on that business development. So what are you seeing in the market that's exciting right now?

[SPEAKER_B] Yeah, so this has been like a really interesting narrative that I've been following, really starting, you know, looking back a couple of years ago where some of these small-to-mid-cap companies were launching their own drugs, sometimes for the first time, maybe it's their first or second drug to reach the market. And they're showing that they can actually do it really well. And they're having quite a bit of success, maybe a little bit different than something that we've seen in the past. And so now they're successfully commercializing independently.

Strategic Intent: The Rise Of Mid-Cap Dealmakers

Read the full transcript

The candid version is on a podcast,
not the earnings call.

Strategic Intent: The Rise Of Mid-Cap Dealmakers

Read the full transcript

The candid version is on a podcast, not the earnings call.

The candid version is on a podcast,
not the earnings call.